Parametric Portfolio Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $45.5M | Sell |
432,584
-5,890
| -1% | -$574K | 0.02% | 590 |
|
|
2021
Q4 | $47.3M | Sell |
438,474
-2,200
| -0.5% | -$240K | 0.02% | 585 |
|
|
2021
Q3 | $48.3M | Buy |
440,674
+30,292
| +7% | +$3.14M | 0.03% | 565 |
|
|
2021
Q2 | $38.4M | Sell |
410,382
-11,717
| -3% | -$1.08M | 0.02% | 667 |
|
|
2021
Q1 | $38.9M | Sell |
422,099
-6,154
| -1% | -$519K | 0.02% | 726 |
|
|
2020
Q4 | $31.3M | Sell |
428,253
-5,891
| -1% | -$438K | 0.02% | 774 |
|
|
2020
Q3 | $33.7M | Sell |
434,144
-2,498
| -0.6% | -$172K | 0.02% | 615 |
|
|
2020
Q2 | $24.3M | Sell |
436,642
-54,344
| -11% | -$2.32M | 0.02% | 766 |
|
|
2020
Q1 | $14.5M | Sell |
490,986
-117,975
| -19% | -$3.99M | 0.01% | 976 |
|
|
2019
Q4 | $22M | Sell |
608,961
-66,555
| -10% | -$2.04M | 0.02% | 929 |
|
|
2019
Q3 | $18.4M | Sell |
675,516
-52,419
| -7% | -$1.36M | 0.01% | 1004 |
|
|
2019
Q2 | $17.5M | Sell |
727,935
-7,659
| -1% | -$194K | 0.01% | 1032 |
|
|
2019
Q1 | $19.4M | Buy |
735,594
+40,959
| +6% | +$971K | 0.02% | 924 |
|
|
2018
Q4 | $13.6M | Buy |
694,635
+34,919
| +5% | +$684K | 0.01% | 1086 |
|
|
2018
Q3 | $12.9M | Sell |
659,716
-36,356
| -5% | -$691K | 0.01% | 1243 |
|
|
2018
Q2 | $11.5M | Buy |
696,072
+9,292
| +1% | +$142K | 0.01% | 1244 |
|
|
2018
Q1 | $9.75M | Buy |
686,780
+26,091
| +4% | +$385K | 0.01% | 1354 |
|
|
2017
Q4 | $9.65M | Sell |
660,689
-129,944
| -16% | -$1.83M | 0.01% | 1352 |
|
|
2017
Q3 | $10M | Buy |
790,633
+384,699
| +95% | +$4.89M | 0.01% | 1253 |
|
|
2017
Q2 | $4.82M | Buy |
405,934
+254,427
| +168% | +$3.16M | 0.01% | 1808 |
|
|
2017
Q1 | $2.24M | Sell |
151,507
-8,686
| -5% | -$141K | ﹤0.01% | 2373 |
|
|
2016
Q4 | $2.59M | Sell |
160,193
-487,590
| -75% | -$8.84M | ﹤0.01% | 2199 |
|
|
2016
Q3 | $11.7M | Buy |
647,783
+137,923
| +27% | +$2.69M | 0.02% | 844 |
|
|
2016
Q2 | $8.4M | Sell |
509,860
-89,161
| -15% | -$1.44M | 0.01% | 1071 |
|
|
2016
Q1 | $9.93M | Buy |
599,021
+296,092
| +98% | +$5.18M | 0.02% | 950 |
|
|
2015
Q4 | $6.56M | Sell |
302,929
-28,471
| -9% | -$554K | 0.01% | 1130 |
|
|
2015
Q3 | $6.57M | Buy |
331,400
+173,994
| +111% | +$5.5M | 0.01% | 943 |
|
|
2015
Q2 | $5.47M | Buy |
157,406
+31,896
| +25% | +$973K | 0.01% | 1242 |
|
|
2015
Q1 | $3.26M | Buy |
125,510
+47,607
| +61% | +$873K | 0.01% | 1762 |
|
|
2014
Q4 | $1M | Sell |
77,903
-44,677
| -36% | -$559K | ﹤0.01% | 2784 |
|
|
2014
Q3 | $1.5M | Sell |
122,580
-11,070
| -8% | -$129K | ﹤0.01% | 2345 |
|
|
2014
Q2 | $2.11M | Sell |
133,650
-2,583
| -2% | -$36.9K | ﹤0.01% | 2025 |
|
|
2014
Q1 | $2.06M | Buy |
136,233
+4,797
| +4% | +$54.2K | ﹤0.01% | 2027 |
|
|
2013
Q4 | $1M | Buy |
131,436
+2,065
| +2% | +$11.1K | ﹤0.01% | 2670 |
|
|
2013
Q3 | $433K | Buy |
129,371
+26,507
| +26% | +$69.9K | ﹤0.01% | 3184 |
|
|
2013
Q2 | $253K | Buy |
+102,864
| New | +$247K | ﹤0.01% | 3361 |
|
Other funds holding HZNP
ACA
PC
Parametric Portfolio Associates's HZNP Position: Q1 2022 in Review
Parametric Portfolio Associates reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 1.3% in Q1 2022, selling an estimated $574K and leaving 432,584 shares worth $45.5M. The position accounts for 0.02% of the portfolio, ranked #590.
Parametric Portfolio Associates first reported a position in HZNP in Q2 2013 and has held it in 36 quarters since. The position peaked at $48.3M in Q3 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.
- Parametric Portfolio Associates held 432,584 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $45.5M as of Q1 2022.
- Parametric Portfolio Associates sold 5,890 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $574K.
- Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of Parametric Portfolio Associates's portfolio in Q1 2022, its #590 holding.
- Parametric Portfolio Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 36 quarters since.
- Parametric Portfolio Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $48.3M in Q3 2021.
- 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.
Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.